Back to Search
CHRISTOPHER ARTEAGA, MD
MD
Gastroenterology Physician
NPI: 1790248177IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
R77233(AZ)
Gastroenterology PhysicianPrimary
Internal Medicine — Gastroenterology
Code: 207RG0100X
34439(FL)ME172124(FL)
CMS Specialties
PrimaryGASTROENTEROLOGY
Education
OTHER
Class of 2019
Research & Publications (20)
Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer.
PMID 19584166·Clin Cancer Res·2009
7-preclinical
ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation.
PMID 19458057·Clin Cancer Res·2009
7-preclinical
Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
PMID 19136975·Nat Chem Biol·2009
8-other
Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists.
PMID 19106609·Cell Cycle·2009
6-review
Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer.
PMID 19435893·Cancer Res·2009
8-other
Brain metastasis: opportunities in basic and translational research.
PMID 19638593·Cancer Res·2009
7-preclinical
Inhibition of PI3K and MEK: it is all about combinations and biomarkers.
PMID 19584146·Clin Cancer Res·2009
7-preclinical
Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton.
PMID 19147560·Cancer Res·2009
8-other
Handedness of children determines preferential facial and eye movements related to hemispheric specialization.
PMID 18813706·Arq Neuropsiquiatr·2008
8-other
Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells.
PMID 19010885·Cancer Res·2008
8-other
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
PMID 18568074·J Clin Invest·2008
7-preclinical
Endoscopic endonasal surgery complication: new methods of intracavernous internal carotid artery injury treatment.
PMID 19408516·Rev Laryngol Otol Rhinol (Bord)·2008
5-case
[Major functional recuperation of branch retinal artery occlusion from thromboses in situ].
PMID 18982050·Can J Ophthalmol·2008
5-case
Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab.
PMID 18625725·Mol Cell Biol·2008
8-other
Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells.
PMID 18579663·Clin Cancer Res·2008
7-preclinical
Knockdown of the transforming growth factor-beta type III receptor impairs motility and invasion of metastatic cancer cells.
PMID 18794117·Cancer Res·2008
7-preclinical
[Neonatal onset of organic acidemia (propionic) diagnosed by tandem mass spectrometry].
PMID 18645657·Biomedica·2008
5-case
Evaluation of biological agents targeted at early-stage disease.
PMID 19128439·Breast Cancer Res·2008
8-other
A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer.
PMID 18829509·Clin Cancer Res·2008
3-trial
Aromatase is phosphorylated in situ at serine-118.
PMID 18822378·J Steroid Biochem Mol Biol·2008
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 305 Clyde Morris Blvd Ste 270
Ormond Beach, FL 32174 - Phone
- (386) 788-1242
Quick Facts
- NPI
- 1790248177
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 2
- Years in Practice
- 7
- Publications
- 20
Are you this provider?
Claim Your Profile